Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $329.7778.

A number of research firms have recently commented on KRYS. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Citigroup upped their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Guggenheim increased their target price on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Wolfe Research assumed coverage on Krystal Biotech in a research note on Friday, March 27th. They issued a “peer perform” rating on the stock.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 642 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the business. UMB Bank n.a. lifted its holdings in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the period. Optimize Financial Inc raised its stake in Krystal Biotech by 1.4% during the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after purchasing an additional 40 shares during the period. Perigon Wealth Management LLC lifted its holdings in Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after purchasing an additional 41 shares in the last quarter. Regal Investment Advisors LLC lifted its holdings in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after purchasing an additional 44 shares in the last quarter. Finally, Torray Investment Partners LLC boosted its stake in Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after purchasing an additional 47 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $323.37 on Wednesday. The firm has a market capitalization of $9.53 billion, a P/E ratio of 43.23 and a beta of 0.53. Krystal Biotech has a one year low of $127.99 and a one year high of $331.49. The business has a fifty day moving average price of $290.96 and a 200-day moving average price of $269.76.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Sell-side analysts expect that Krystal Biotech will post 7.83 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.